In biologic-naïve UC patients, does vedolizumab achieve higher rates of clinical remission at 52 weeks than ustekinumab

What is known

- In Crohn's disease, Lenti et al. found no superiority of ustekinumab over vedolizumab at week 14 or week 52, and Onali et al. found ustekinumab non-significantly better for clinical remission. ¹ - UC comparative data in the corpus are vedolizumab vs anti-TNF: a 303-patient biologic-naïve cohort showed higher clinical remission with vedolizumab than anti-TNF (HR 1.67, 95% CI 1.15-2.43). ² - Guideline data compare vedolizumab with adalimumab in UC (VARSITY-type), showing no significant 52-week remission difference in the steroid-baseline subgroup — ustekinumab is not part of this comparison. ³

What is unknown / caveats

- No direct vedolizumab-vs-ustekinumab UC comparison in the retrieved excerpts - The head-to-head comparative data available are in Crohn's disease, not UC - UC comparisons retrieved involve anti-TNF, not ustekinumab - The retrieved corpus does not contain a biologic-naïve UC study answering this specific 52-week vedolizumab-vs-ustekinumab question.

## References

1. Mocci G, Tursi A, Onidi FM, Usai-Satta P, Pes GM, Dore MP. Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms. J Clin Med. 2024;13(5):ePub only. PMID: 38592377.

2. Hahn GD, Golovics PA, Wetwittayakhlang P, Al Khoury A, Bessissow T, Lakatos PL. Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?. Biomedicines. 2022;10(4). PMID: 35453498.

3. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. PMID: 31562236.

For educational use only — not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft — generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._